SARS-CoV-2, has caused an international outbreak of respiratory illness termed Covid-19. The investigators used peptides derived from SARS-CoV-2 virus, to study viral-specific immune responses. COV-CREM is a French prospective monocentric study that will evaluate viral-specific cell responses in positive patients for SARS-CoV-2 on the basis of (RT-PCR) assay performed in respiratory tract sample tested by our local Center for Disease Control.
Other: Additional biological samples
Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.
Other Name: Additional blood samples will be realized as part of the care
Inclusion Criteria:
- COVID-19 PCR positive,
- Hospitalized patients with illness of any duration, and/or SpO2 ≤ 92% on room air.
- Cohorte C : patients with cancer (hematological malignancies and solid tumors).
Exclusion Criteria:
- Refusal to participate,
- Any immunosuppressive therapy (i.e. corticosteroids >10mg of hydrocortisone or
equivalent dose) within 14 days before the planned start of study,
- Active or chronic hepatitis B or C and/or HIV positive (HIV 1/2 antibodies patients),
or a known history of active Tuberculosis bacillus,
- Active autoimmune disease that required a systemic treatment, with the following
exceptions:
- Patients with a history of autoimmune-related hypothyroidism who are on thyroid
replacement hormone are eligible for the study,
- Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen
are eligible for the study,
- Prior allogeneic bone marrow transplantation or prior solid organ transplantation,
- Patients currently exposed to chemotherapy, anti-tumor immunotherapy as anti-PD-1,
anti-PD-L1, or anti-CTLA4 agent or any immune therapy or biotherapy (except for
patients in cohort C),
- Previous prescribing of biotherapy or treatment for the management of COVID-19 is not
an exclusion criterion,
- Patient under guardianship, curatorship or under the protection of justice.
CHU Jean Minjoz
Besançon, France
Investigator: Marie KROEMER, PharmD PhD
mkroemer@chu-besancon.fr
Marie KROEMER, PharmD PhD
0370632281
mkroemer@chu-besancon.fr
Kevin BOUILLER, MD
kbouiller@chu-besancon.fr